Medications and retinal toxicity

Ophthalmology Clinics of North America

Volumn 15, Issue 4, 2002, Pages 517-528

  Schwartz, Stephen G ^a   Mieler, William F ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CULLEN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ADRENALIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMINOGLYCOSIDE; CANTHAXANTHIN; CHLOROQUINE; CHLORPROMAZINE; CLOFAZIMINE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; DIDANOSINE; DIGITALIS; DIPIVEFRINE; HYDROCHLOROTHIAZIDE; HYDROXYCHLOROQUINE; LATANOPROST; MAGNESIUM SILICATE; METHADONE; METHANOL; METHOXYFLURANE; METHYLPHENIDATE; METRONIDAZOLE; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; QUININE; RIFABUTIN; SILDENAFIL; TAMOXIFEN; THIORIDAZINE; UNINDEXED DRUG;

HUMAN; PRIORITY JOURNAL; RETINOPATHY; REVIEW;

DRUG THERAPY; HUMANS; OPHTHALMIC SOLUTIONS; RETINA; RETINAL DISEASES;

EID: 0036950905     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-1549(02)00051-2     Document Type: Review

References (130)

1. Cambiaggi A. Unusual ocular lesions in a case of systemic lupus erythematosus. Arch Ophthalmol 1957;57:451-3.
2. Henkind P, Rothfield NF. Ocular abnormalities in patients treated with synthetic antimalarial drugs. N Engl J Med 1963;269:433-9.
3. Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet 1959;2:478-80.
4. Okun E, Gouras P, Berstein H, von Sallman L. Chloroquine retinopathy. Arch Ophthalmol 1963; 69:59-71.
5. Hart WM, Burde RM, Johnston GP, Drews RC. Static perimetry in chloroquine retinopathy: Perifoveal patterns of visual field depression. Arch Ophthalmol 1984;102:377-80.
6. Easterbrook M. The use of Amsler grids in early chloroquine retinopathy. Ophthalmology 1984;91: 1368-72.
7. Vu BLL, Easterbrook M, Hovis JK. Detection of color vision defects in chloroquine retinopathy. Ophthalmology 1999;106:1799-804.
8. Ochsendorf FR,Runne U. Chloroquine: Consideration of maximum daily dose (3.5 mg/kg ideal weight) prevents retinopathy. Dermatology 1996; 192:382-3.
9. Brinkley JR, Dubois EL, Ryan SJ. Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol 1979;88:1-11.
10. Carr RE, Henkind P, Rothfield N, Siegel IM. Ocular toxicity of antimalarial drugs. Am J Ophthalmol 1968;66:738-44.
11. Ehrenfeld M, Nesher R, Merin S. Delayed-onset chloroquine retinopathy. Br J Ophthalmol 1986;70: 281-3.
12. Sassani JW, Brucker AJ, Cobbs W, Campbell C. Progressive chloroquine retinopathy. Ann Ophthalmol 1983;15:19-22.
13. Rubin M, Bernstein HN, Zvaifler NJ. Studies on the pharmacology of chloroquine. Arch Ophthalmol 1963; 70:80-7.
14. Shearer RV, Dubois EL. Ocular changes induced by long-term hydroxychloroquine therapy. Am J Ophthalmol 1967;64:245-52.
15. Weiner A, Sandberg MA, Gaudio AR, Kini MM, Berson EL. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991;112:528-34.
16. Fielder A, Graham E, Jones S, Silman A, Tullo A. Royal College of Ophthalmologists guidelines: Ocular toxicity and hydroxychloroquine. Eye 1998;12: 907-9.
17. Morsman CDG, Livesey SJ, Richards IM, Jessop JD, Mills PV. Screening for hydroxychloroquine retinal toxicity: Is it necessary? Eye 1990;4:572-6.
18. Silman A, Shipley M. Ophthalmological monitoring for hydroxychloroquine toxicity: A scientific review of available data. Br J Rheumatol 1997;36:599-601.
19. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF, for the American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmol 2002;109:1377-82.
20. Tekell JI, Silva JA, Maas JA, Bowden CL, Starck T. Thioridazine-induced retinopathy. Am J Psychiatry 1996;153:1234-5.
21. Weekley RD, Potts AM, Reboton J, May RH. Pigmentary retinopathy in patients receiving high doses of a new phenothiazine. Arch Ophthalmol 1960;64: 65-76.
22. Meredith TA, Aaberg TM, Willerson D. Progressive chorioretinopathy after receiving thioridazine. Arch Ophthalmol 1978;96:1172-6.
23. Miller III FS, Bunt-Milam AH, Kalina RE. Clinical-ultrastructural study of thioridazine retinopathy. Ophthalmoklogy 1982;89:1478-88.
24. Connell MM, Poley BJ, McFarlane JR. Chorioretinopathy associated with thioridazine therapy. Arch Ophthalmol 1964;71:816-21.
25. Neves MS, Jordan K, Dragt H. Extensive chorioretinopathy associated with very low dose thioridazine [letter]. Eye 1990;4:767-70.
26. MacKenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983;75:40-5.
27. Marmor MF. Is thioridazine retinopathy progressive? Relationship of pigmentary changes to visual function. Br J Ophthalmol 1990;74:739-42.
28. DeLong SL, Poley BJ, McFarlane Jr JR. Ocular changes associated with long-term chlorpromazine therapy. Arch Ophthalmol 1965;73:611-7.
29. Wolfensberger TJ. Toxicology of the retinal pigment epithelium. In: Marmor MF, Wolfensberger TJ, editors. The Retinal Pigment Epithelium: Function and Disease. New York: Oxford University Press; 1998. p. 621-47.
30. Mathalone MBR. Eye and skin changes in psychiatric patients treated with chlorpromazine. Br J Ophthalmol 1967;51:86-93.
31. Siddall JR. The ocular toxic findings with prolonged and high dosage chlorpromazine intake. Arch Ophthalmol 1965;74:460-4.
32. Zelickson AS, Zeller HC. A new and unusual reaction to chlorpromazine. JAMA 1964;188:394-6.
33. McClanahan WS, Harris JE, Knobloch WH, Tredici RL, Udasco RL. Ocular manifestations of chronic phenothiazine derivative administration. Arch Ophthalmol 1966;75:319-25.
34. Brinton GS, Norton EWD, Zahn JR, Knighton RW. Ocular quinine toxicity. Am J Ophthalmol 1980;90: 403-10.
35. Bacon P, Spalton DJ, Smith SE. Blindness from quinine toxicity. Br J Ophthalmol 1988;72:219-24.
36. Gass JDM. Stereoscopic Atlas of Mascular Diseases: Diagnosis and Treatment. 4th Edition. St. Louis: Mosby-Year Book; 1997. p. 782.
37. Davies SC, Hungerford JL, Arden GB, et al. Ocular toxicity of high-dose intravenous desferrioxamine Lancet 1983;2:181-4.
38. Spraul CW, Schicketanz C, Lang GE. Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemachromatosis. Klin Monatsbl Augenheilkd 1996;209:31-6.
39. Bene C, Manzler A, Bene D, Kranias G. Irreversible ocular toxicity from single "challenge" dose of deferoxamine. Clin Nephrol 1989;31:43-8.
40. Craythorn JM, Swartz M, Creel DJ. Clofazimine-induced bull's-eye retinopathy. Retina 1986;6:50-2.
41. Cunningham CA, Friedberg DN, Carr RE. Clofazimine-induced generalized retinal degeneration. Retina 1990;10:131-4.
42. Forster DJ, Causey DM, Rao NA. Bull's eye retinopathy and clofazimine. Ann Intern Med 1992;116: 876-7.
43. Cobo J, Ruiz MF, Figueroa MS, et al. Retinal toxicity associated with didanosine in HIV-infected adults. AIDS 1996;10:1297-300.
44. Nguyen BT, Shay LE, Wyvill KM, et al. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection. J Infect Dis 1993;168:810-7.
45. Whitcup SM, Butler KM, Caruso R, et al. Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine. Am J Ophthalmol 1992;113:1-7.
46. Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 1994; 117:772-5.
47. McKeown CA, Swartz M, Blom J, Maggiano JM. Tamoxifen retinopathy. Br J Ophthalmol 1981;65: 177-9.
48. Gorin MB, Day R, Constantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998;125:493-501.
49. Espaillat A, Aiello LP, Arrigg PG, et al. Canthaxanthine retinopathy. Arch Ophthalmol 1999;117: 412-3.
50. Chang TS, Aylward W, Clarkson JG, Gass JDM. Asymmetric canthaxanthine retinopathy. Am J Ophthalmol 1995;119:801-2.
51. Cortin P, Boudreault G, Rousseau AP, Tardif Y, Malenfant M. La retinopathie a la canthaxanthine, II: Facteurs predisposants. Can J Ophthalmol 1984; 19:215-9.
52. Harnois C, Cortin P, Samson J, et al. Static perimetry in canthaxanthine maculopathy. Arch Ophthalmol 1988;106:58-60.
53. Willson RL, Ross RD, Willson LM, Cohen G, Redfield TL, Gitter KA. Interferon-associated retinopathy in a young, insulin-dependent diabetic patient. Retina 2000;20:413-5.
54. nd Edition. New York: Churchill Livingstone; 1989. p. 64.
55. Bullock JD, Albert DM. Fleck retina: Appearance secondary to oxalate crystals from methoxyflurane anesthesia. Arch Ophthalmol 1975;93:26-31.
56. Novak MA, Roth AS, Levine MR. Calcium oxalate retinopathy associated with methoxyflurane abuse. Retina 1988;8:230-6.
57. Withering W. An Account of The Foxglove, and Some of Its Medical Uses: With Practical Remarks on Dropsy and Other Diseases. London: Robinson; 1785.
58. Piltz JR, Wertenbaker C, Lance SE, Slamovits T, Leeper HF. Digoxin toxicity: Recognizing the varied visual presentations. J Clin Neuro-Ophthalmol 1993; 13:275-80.
59. Madreperla SA, Johnson MA, Nakatani K. Electrophysiologic and electroretinographic evidence for photoreceptor dysfunction as a toxic effect of digoxin. Arch Ophthalmol 1994;112:807-12.
60. Weleber RG, Shults WT. Digoxin retinal toxicity: Clinical and electrophysiologic evaluation of a cone dysfunction syndrome. Arch Ophthalmol 1981;99: 1568-72.
61. Ballard SA, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159:2164-71.
62. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-404.
63. Burton AJ, Reynolds A, O'Neill D. Sildenafil (Viagra): A cause of proliferative diabetic retinopathy [letter]? Eye 2000;14:785-6.
64. Marmor MF, Kessler R. Sildenafil (Viagra) and ophthalmology. Surv Ophthalmol 1999;44:153-62.
65. Tripathi A, O'Donnell NP. Branch retinal artery occlusion: Another complication of sildenafil [letter]. Br J Ophthalmol 2000;84:928.
66. Baumbach GL, Cancilla PA, Martin-Amat G, et al. Methyl alcohol poisoning, IV: Alterations of the morphological findings of the retina and optic nerve. Arch Ophthalmol 1977;95:1859-65.
67. Hayreh MS, Hayreh SS, Baumbach GL, et al. Methyl alcohol poisoning, III: Ocular toxicity. Arch Ophthalmol 1977;95:1851-8.
68. Ingemansson SO. Clinical observations on ten cases of methanol poisoning. Acta Ophthalmol 1984; 62:15-24.
69. Brown GC, Eagle RC, Shakin EP, Gruber M, Arbizio VV. Retinal toxicity of intravitreal gentamicin. Arch Ophthalmol 1990;108:1740-4.
70. Campochiaro PA, Conway BP. Aminoglycoside toxicity - A survey of retinal specialists: Implications for ocular use. Arch Ophthalmol 1991;109: 946-50.
71. Campochiaro PA, Lim JI, et al. Aminoglycoside toxicity in the treatment of endophthalmitis. Arch Ophthalmol 1994;112:48-53.
72. McDonald HR, Schatz H, Allen AW, et al. Retinal toxicity secondary to intraocular gentamicin. Ophthalmology 1986;93:871-7.
73. AtLee WE. Talc and cornstarch emboli in eyes of drug users. JAMA 1972;219:49.
74. Tse DT, Ober RR. Talc retinopathy. Am J Ophthalmol 1980;90:624-40.
75. Brucker AJ. Disk and peripheral neovascularization secondary to talc and cornstarch emboli. Am J Ophthalmol 1979;88:864.
76. Friberg TR, Gragoudas ES, Regan CDJ. Talc emboli and macular ischemia in intravenous drug abuse. Arch Ophthalmol 1979;97:1089.
77. Jampol LM, Setogawa T, Rednam KRV, Tso MOM. Talc retinopathy in primates: A model of ischemic retinopathy, I: Clinical studies. Arch Ophthalmol 1981; 99:1273-80.
78. Kresca LJ, Goldberg MF, Jampol LM. Talc emboli and retinal neovascularization in a drug abuser. Am J Ophthalmol 1979;87:334.
79. Gombos GM, Moreno DH, Bedrossian PB. Retinal vascular occlusion induced by oral contraceptives. Ann Ophthalmol 1975;7:215-7.
80. Perry HD, Mallen FJ. Cilioretinal artery occlusion associated with oral contraceptives. Am J Ophthalmol 1977;84:56-8.
81. Stowe GC, Jakov AN, Albert DM. Central retinal vascular occlusion associated with oral contraceptives. Am J Ophthalmol 1978;86:798-801.
82. Varga M. Recent experiences on the ophthalmological complications of oral contraceptives. Ann Ophthalmol 1976;8:925-34.
83. Walsh FB, Clark DB, Thompson RS, Nicholson DH. Oral contraceptives and neuro-ophthalmologic interest. Arch Ophthalmol 1965;74:628-40.
84. Lake SR, Vernon SA. Emergency contraception and retinal vein thrombosis [letter]. Br J Ophthalmol 1999; 83:628.
85. Reddy A, Edesten C, Hardman-Lea S. A transsexual patient with bilateral central retinal vein occlusions [letter]. Eye 2000;14:104-5.
86. Garg SK, Chase P, Marshall G, et al. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 1994;271:1099-102.
87. Petersson GJ, Fraunfelder FT, Meyer SM. Oral contraceptives. Ophthalmology 1981;88:368-71.
88. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111:350-6.
89. Hejny C, Sternberg P, Lawson DH, Greiner K, Aaberg Jr TM. Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol 2001;131:782-7.
90. Thomas JV, Gragoudas ES, Blair NP, Lapus JV. Correlation of epinephrine use and macular edema in aphakic glaucomatous eyes. Arch Ophthalmol 1978; 96:625-8.
91. Mehelas TJ, Kollarits CR, Martin WG. Cystoid macular edema presumably induced by dipivefrin hydrochloride (propine). Am J Ophthalmol 1984;94:682.
92. Hoyng PFJ, Rulo AH, Greve EL, Astin M, Gjotterberg M. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: A review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol 1997; 41(suppl 2):S83-8.
93. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Ophthalmology 1998;105:263-8.
94. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol 1998;126: 602-4.
95. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol 1997;124:683-5.
96. Lima MC, Paranhos Jr A, Salim S, et al. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma 2000;9:317-21.
97. Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999;106: 1024-9.
98. Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol 1995;79:54-6.
99. Gass JDM. Nicotinic acid maculopathy. Am J Ophthalmol 1973;76:500-10.
100. Millay RH, Klein ML, Illingworth DR. Niacin maculopathy. Ophthalmology 1988;95:930-6.
101. Jampol LM. Niacin maculopathy. Ophthalmology 1988;95:1704-5.
102. Grinbaum A, Ashkenazi I, Avni I, Blumenthal M. Transient myopia following metronidazole treatment for trichomonas vaginalis. JAMA 1992;267:511-2.
103. Maddalena MA. Transient myopia associated with acute glaucoma and retinal edema: Following vaginal administration of sulfanilamide. Arch Ophthalmol 1968;80:186-8.
104. Ryan EH, Jampol LM. Drug-induced acute transient myopia with retinal folds. Retina 1986;6:220-3.
105. Soylev MF, Green RL, Feldon SE. Choroidal effusion as a mechanism for transient myopia induced by hydrochlorothiazide and traimterene. Am J Ophthalmol 1995;120:395-7.
106. Jacobs DS, Piliero PJ, Kuperwaser MG, et al. Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection. Am J Ophthalmol 1994;118:716-22.
107. Karbassi M, Nikou S. Acute uveitis in patients with acquired immunodeficiency syndrome receiving prophylactic rifabutin. Arch Ophthalmol 1995;113: 699-701.
108. Rifai A, Peyman GA, Daun M, Wafapoor H. Rifabutin- associated uveitis during prophylaxis for Mycobacterium avium complex infection. Arch Ophthalmol 1995;113:707.
109. Chaknis MJ, Brooks SE, Mitchell KT, Marcus DM. Inflammatory opacities of the vitreous in rifabutin-associated uveitis. Am J Ophthalmol 1996;122:580-2.
110. Johnson TM, Desroches G. Panuveitis associated with rifabutin prophylaxis in a pediatric HIV-positive patient. J Pediatr Ophthalmol Strabismus 1998;35: 119-21.
111. Khan MA, Singh J, Dhillon B. Rifabutin-induced uveitis with inflammatory vitreous infiltrate. Eye 2000; 14:344-6.
112. Akler ME, Johnson DW, Bruman WJ, et al. Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis. Ophthalmology 1998;105:651-7.
113. Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:733-7.
114. Kirsch LS, Arevalo JF, de la Paz EC. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1995;102:533-43.
115. Rahal FM, Arevalo JF, Munguia D, et al. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology 1996;103: 1078-83.
116. nd BW, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-8.
117. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986;101:190-5.
118. Pendergast SD, Eliott D, Machemer R. Retinal toxic effects following inadvertent intraocular injection of Celestone Soluspan. Arch Ophthalmol 1995;113: 1230-1.
119. Yannuzzi LA, Guyer DR, Green WR, editors. The Retina Atlas. St. Louis: Mosby-Year Book; 1995. p. 709.
120. Grimson BS, Mahely Jr MS, Dubey HD, et al. Ophthalmic and central nervous system complications following intra-carotid BCNU (Carmustine). J Clin Neuro-Ophthalmol 1981;1:261-4.
121. Miller DF, Bay JW, Lederman RJ, et al. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 1985;92:402-6.
122. Shingleton BJ, Bienfang DC, Albert DM, et al. Ocular toxicity associated with high dose carmustine. Arch Ophthalmol 1982;100:1766-72.
123. Kupersmith MJ, Frohman LP, Choi IS, et al. Visual system toxicity following intra-arterial chemotherapy. Neurology 1988;38:284-9.
124. Khawly JA, Rubin P, Petros W, Peters WP, Jaffe GJ. Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. Ophthalmology 1996;103:87-95.
125. Margo CE, Murtagh FR. Ocular and orbital toxicity after intracarotid cisplatin therapy. Am J Ophthalmol 1993;116:508-9.
126. Hilliard LM, Berkow RL, Watterson J, et al. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Ped Oncol 1997;28:31-3.
127. Kupersmith MJ, Seiple WH, Holopigian K, et al. Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. Am J Ophthalmol 1992;113:435-8.
128. Ravelli M, Scaroni P, Mombelloni S, et al. Acute visual disorders in patients on regular dialysis given desferrioxamine as a test. Nephrol Dial Transplant 1990;5:945-9.
129. Wang MY, Arnold AC, Vinters HV, Glasgow BJ. Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. Am J Ophthalmol 2000;130:367-8.
130. Weber U, Goerz G, Hennekes R. Carotenoid retinopathie, I: Morphologische und funktionell befunde. Klin Mbl Augenheilkd 1985;186:351-4.